ArticleFrontiers of medicine2025
Mutually reinforcing relationship between Sjögren's syndrome and lung adenocarcinoma: insights from Mendelian randomisation, single-cell, and transcriptomic analyses.
Article in Frontiers of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence suggests an association between Sjögren's syndrome (SS) and multiple cancers; however, the causal relationships and regulatory mechanisms remain unclear. Using European genome-wide association study data, we employed Mendelian randomisation (MR) and meta-analysis to explore the SS-cancer causality. Bidirectional two-sample MR revealed that SS increased the risk of colorectal (odds ratio (OR) = 1.08) and lung cancers (OR = 1.15), whereas lung (OR = 3.03) and female genital cancers (OR = 6.59) were found to elevate the risk of SS. Co-localisation analysis confirmed bidirectional causality between SS and lung cancer. Summary data-based MR identified HLA-DPB2 as a hub gene, with single-cell RNA and mRNA analyses suggesting its role in memory B cells regulation via MHC-II ligands and lung carcinogenesis. This study demonstrates a mutually positive association between SS and lung cancer, implicating HLA-DPB2 as a potential regulatory gene and offering novel insights into the relationship between SS and cancer, especially lung cancer.
Indexed as
Identifiers
41212483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.